Objectives: Pioglitazone (PGZ), an insulin-sensitizing agent, has been reported to alter circulating
lipids, including triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C),
and adiponectin (ADPN) levels. However, clinical effects of PGZ on the quality of
lipoproteins have not been fully defined. We aimed to clarify the clinical association
of PGZ treatment with the ratios of lipoproteins to apolipoproteins and the ADPN levels
in statin-treated diabetes patients.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
EAS-0268
Identification
Copyright
© 2014 Published by Elsevier Inc.
